Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract

PRINCETON, N.J., March 23, 2016 -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer Research (AACR) Annual Meeting. The Research Reception, for which registration is required, will be held at 6:30 PM CT on April 18, 2016 at the Sheraton New Orleans Hotel in New Orleans, Louisiana.

The Advaxis Research Reception will feature two presentations:

• Lm Immunotherapy: Impact within the Tumor Microenvironment
  • A review of the late-breaking poster presentation (Abstract #LB-095) on the immunogenicity of Advaxis’ lead immunotherapy candidate, axalimogene filolisbac, as preoperative treatment prior to robotic-assisted surgery in patients with HPV-associated head and neck cancer.
    • Rosemarie Krupar, MD, Baylor College of Medicine
  • Immunogenicity of ADXS-HER2 in Canine Osteosarcoma
    • Nicola Mason, PhD, BVetMed, Assistant Professor of Medicine, University of Pennsylvania
  • Effects of Advaxis’ Lm Immunotherapy on the STING Pathway
    • Robert Petit, PhD, Chief Scientific Officer, Advaxis
• Cancer Neoepitope Immunotherapy: An Update on ADXS-NEO
  • Robert Petit, PhD, Chief Scientific Officer, Advaxis

Attendees will also have the opportunity to view the late breaking Phase 2 poster featured at AACR and ask questions of the lead author. Space is limited and registration, which is required, can be completed online at: www.regonline.com/advaxisreception2016.

About Advaxis, Inc.

Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology™, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against cancer antigens and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology™ immunotherapy, axalimogene filolisbac, targets human papilloma virus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development.

For additional information on Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

Forward-Looking Statements

This media statement contains forward-looking statements, including, but not limited to: statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2015, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

CONTACTS:

Company:
Advaxis, Inc.
Greg Mayes, Executive Vice President and COO
[email protected]
609.250.7515

Media Contact:
JPA Health Communications
Catherine Brady
[email protected]
617.945.9316